InCode BioPharmaceutics, a Lahaina, Hawaii, biotech targeting autoimmune and inflammatory disease, raised $2 million in a second funding round, VentureWire reports (subscription required). The funding was provided by Avalon Ventures.
InCode is developing what VentureWire vaguely describes as "therapeutic uses for certain amino-acid sequences in non-human proteins," which sounds like they've bioharvested some peptides from other organisms that seem to have interesting properties. The company said the funding will carry its lead compound, which it calls rC3Decomplase, through preclinical lab and animal testing over the next 18 months.